![]() |
Name |
2,2-Dimethyl-1-oxaspiro[2.5]octan-4-one
|
Molecular Formula | C9H14O2 | |
IUPAC Name* |
2,2-dimethyl-1-oxaspiro[2.5]octan-4-one
|
|
SMILES |
CC1(C2(O1)CCCCC2=O)C
|
|
InChI |
InChI=1S/C9H14O2/c1-8(2)9(11-8)6-4-3-5-7(9)10/h3-6H2,1-2H3
|
|
InChIKey |
KHMIGEOLXGGVMM-UHFFFAOYSA-N
|
|
Synonyms |
2,2-Dimethyl-1-oxaspiro[2.5]octan-4-one; 50786-09-9; 2-Isopropylidenecyclohexanone oxide; 1-Oxaspiro[2.5]octan-4-one, 2,2-dimethyl-; 2,2-Dimethyl-1-oxaspiro[2.5]octan-4-one #
|
|
CAS | NA | |
PubChem CID | 586890 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 154.21 | ALogp: | 0.9 |
HBD: | 0 | HBA: | 2 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 29.6 | Aromatic Rings: | 2 |
Heavy Atoms: | 11 | QED Weighted: | 0.501 |
Caco-2 Permeability: | -4.55 | MDCK Permeability: | 0.00002570 |
Pgp-inhibitor: | 0.002 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.004 | 20% Bioavailability (F20%): | 0.036 |
30% Bioavailability (F30%): | 0.028 |
Blood-Brain-Barrier Penetration (BBB): | 0.987 | Plasma Protein Binding (PPB): | 63.57% |
Volume Distribution (VD): | 1.443 | Fu: | 45.52% |
CYP1A2-inhibitor: | 0.059 | CYP1A2-substrate: | 0.861 |
CYP2C19-inhibitor: | 0.103 | CYP2C19-substrate: | 0.919 |
CYP2C9-inhibitor: | 0.044 | CYP2C9-substrate: | 0.213 |
CYP2D6-inhibitor: | 0.005 | CYP2D6-substrate: | 0.439 |
CYP3A4-inhibitor: | 0.018 | CYP3A4-substrate: | 0.557 |
Clearance (CL): | 8.776 | Half-life (T1/2): | 0.869 |
hERG Blockers: | 0.008 | Human Hepatotoxicity (H-HT): | 0.25 |
Drug-inuced Liver Injury (DILI): | 0.825 | AMES Toxicity: | 0.894 |
Rat Oral Acute Toxicity: | 0.482 | Maximum Recommended Daily Dose: | 0.044 |
Skin Sensitization: | 0.088 | Carcinogencity: | 0.946 |
Eye Corrosion: | 0.013 | Eye Irritation: | 0.251 |
Respiratory Toxicity: | 0.606 |